ClinicalTrials.gg
Sign In

Drug

Anti-CD7 CAR-T Cells RD13-02 clinical trials

studies test it
8
open now
2
in phase 3
0
first study started
2023

Keep track of what changes. Save the Anti-CD7 CAR-T Cells RD13-02 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

RD13-02 cell infusion
7

Development codes

RD13-02
1

Studies by the year they started

8 studies that test it; most in 2023 (5)

Studies that test Anti-CD7 CAR-T Cells RD13-02, by start year
YearStudies
20235
20241
20252

By phase

A phase 1/2 study counts in both.

Early Phase 1
6
Phase 1
2

What it is tested for

Each study’s main condition, where its own words name it.

Hematologic Neoplasms
6
Diabetes Mellitus, Type 1
1
Anemia, Aplastic
1

Who runs them

Industry 1 · Other 7

Nanjing Bioheng Biotech Co., Ltd. (1) · MEI HENG (1) · Henan Cancer Hospital (1) · He Huang (1) · Kai Lin Xu，MD (1) · Xiaoyu Zhu (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Wuhan Union Hospital, China (1)

Studies

Open first, then newest update. How each study uses Anti-CD7 CAR-T Cells RD13-02 is read from its arms, and is right about nine times in ten.

Testing it · 8